Claim your 20% discount on Global Market Reports with code ONLINE20. Limited time only.

How Much Will The Asthma Disease Market Be Worth By 2029?

In recent times, the market size for asthma disease has seen significant growth. It’s estimated to rise from $24.63 billion in 2024 and reach a value of $25.93 billion in 2025, representing a compound annual growth rate (CAGR) of 5.3%. The prior growth can be largely credited to the increasing instances of asthma among urban dwellers, escalating levels of air pollution in industrial areas, heightened awareness surrounding asthma symptoms and their diagnosis, the growing usage of corticosteroids and bronchodilators, as well as the widening reach of healthcare in developing countries.

The market for asthma disease is predicted to experience robust expansion in the forthcoming years, poised to reach $31.56 billion in 2029 with a compound annual growth rate (CAGR) of 5.0%. Factors such as an escalating acceptance of biologics for serious asthma, the growing demand for tailored medication, increased asthma research investments, the rise of digital health and remote monitoring, and wider reach of telemedicine services for managing asthma are attributing to the growth expected in the forecast period. Key trends during this period encompass breakthroughs in biologic treatments for severe asthma, technological upgrades in inhalers with intelligent features, the invention of AI-driven tools for asthma monitoring, inventiveness in individualized asthma therapy methods, and the evolution of digital health platforms for overseeing asthma remotely.

Get A Free Sample Of The Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=25701&type=smp

Which Key Factors Are Fueling Growth In The Asthma Disease Market?

The asthma disease market is anticipated to experience growth, driven by the increasing occurrence of respiratory disorders. These disorders, which include ailments such as chronic obstructive pulmonary disease (COPD), bronchitis, and asthma, have an adverse effect on the lungs and breathing. The rise in these disorders can be attributed to the irritation and inflammation of the airways caused by particulate matter and nitrogen oxides, resulting in breathing challenges and the exacerbation of conditions like asthma. Inflammation and airway remodeling due to respiratory diseases can induce or intensify asthma symptoms. As per the National Library of Medicine, a national library in the US, it was projected in December 2023, that by 2050, COPD instances in low- and middle-income countries would be over double those in high-income countries. It was also anticipated that sub-Saharan Africa will witness a 59% increase in COPD, making it the global leader in COPD prevalence and cases by 2040. Therefore, the upsurge in respiratory disorders is fuelling the expansion of the asthma disease market.

Which Segmentation Factors Are Critical In The Asthma Disease Market Analysis?

The asthma disease market covered in this report is segmented –

1) By Treatment Type: Controller Medications, Rescue Medications, Biologics, Combination Therapy

2) By Cause Of Asthma: Allergic Asthma, Non-Allergic Asthma, Exercise-Induced Asthma, Occupational Asthma

3) By Severity: Mild Intermittent, Mild Persistent, Moderate Persistent, Severe Persistent

4) By Route Of Administration: Oral, Inhaled, Intravenous, Other Route Of Administration

5) By End-Users: Hospitals, Homecare, Specialty Clinics , Others End-Users

Subsegments:

1) By Controller Medications Inhaled Corticosteroids (ICS), Long-Acting Beta-Agonists (LABA), Leukotriene Receptor Antagonists (LTRA), Long-Acting Muscarinic Antagonists (LAMA), Methylxanthines

2) By Rescue Medications: Short-Acting Beta-Agonists (SABA), Systemic Corticosteroids, Anticholinergics

3) By Biologics: Anti-IGE Therapy, Anti-IL-5 Therapy, Anti-IL-4/IL-13 Therapy, Anti-TSLP Therapy

4) By Combination Therapy: ICS Or LABA Combinations, ICS Or LABA Or LAMA Combinations, ICS Or LAMA Combinations

What Are The Dominant Trends Currently Seen In The Asthma Disease Market?

Leading firms in the asthma disease market are concentrating their efforts on creating monoclonal antibody therapies, with a goal of improving treatment outcomes and effectiveness. This type of targeted therapy involves the use of fabricated proteins that imitate the immune system’s defensive properties against harmful intruders, thus making the management of chronic disorders like asthma more accurate and efficient. For example, in June 2022, the National Institutes of Health (NIH), a medical research unit based in the US, initiated the PANDA (preventing asthma in high-risk children) trial to assess dupilumab, a monoclonal antibody, as a potential treatment for asthma in urban children. The PANDA trial is a stage-2, randomized, placebo-controlled study testing dupilumab on roughly 240 children, aged 6-17, suffering from poorly controlled, type 2 inflammation, severe allergy-induced asthma residing in low-income urban neighborhoods. These participants receive subcutaneous injections bi-weekly for a year, along with regular asthma care and at a 2:1 randomization ratio to dupilumab or placebo. Additionally, the trial aims to comprehend the asthma exacerbation molecular pathways and treatment response in this vulnerable pediatric group through mechanistic studies using nasal swabs and blood samples for examining gene expression, specifically during respiratory viral infections.

Which Players Are Shaping The Competitive Landscape Of The Asthma Disease Market?

Major companies operating in the asthma disease market are Pfizer Inc., Johnson & Johnson, F. Hoffmann-La Roche Ltd., Merck & Co. Inc., AbbVie Inc., Novartis AG, Sanofi S.A., AstraZeneca PLC, Abbott Laboratories, GlaxoSmithKline plc, Eli Lilly and Company, Amgen Inc., Boehringer Ingelheim GmbH, Teva Pharmaceutical Industries Ltd., Regeneron Pharmaceuticals Inc., Astellas Pharma Inc., Chiesi Farmaceutici S.p.A., Cipla Limited, Mundipharma International Limited, Generate Biomedicines.

Access The Complete Report Here:

https://www.thebusinessresearchcompany.com/report/asthma-disease-global-market-report

Which Region Is Likely To Register The Fastest Growth In The Asthma Disease Market?

North America was the largest region in the asthma disease market in 2024. The regions covered in the asthma disease market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Customize Your Report Here:

https://www.thebusinessresearchcompany.com/customise?id=25701&type=smp

Browse Through More Reports Similar to the Global Asthma Disease Market 2025, By The Business Research Company

Asthma Spacers Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/asthma-spacers-global-market-report

Chronic Obstructive Pulmonary Disease Copd And Asthma Devices Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/chronic-obstructive-pulmonary-disease-copd-and-asthma-devices-global-market-report

Black Lung Disease Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/black-lung-disease-global-market-report

About The Business Research Company:

With over 17500+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model